Provided by Tiger Fintech (Singapore) Pte. Ltd.

PharmaCyte Biotech, Inc.

0.8900
-0.0274-2.99%
Volume:34.76K
Turnover:31.15K
Market Cap:6.05M
PE:141.40
High:0.9174
Open:0.9000
Low:0.8800
Close:0.9174
52wk High:1.94
52wk Low:0.8000
Shares:6.80M
Float Shares:6.08M
Volume Ratio:0.87
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0063
EPS(LYR):3.19
ROE:-2.33%
ROA:-4.29%
PB:0.14
PE(LYR):0.28

Loading ...

Company Profile

Company Name:
PharmaCyte Biotech, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
2
Office Location:
3960 Howard Hughes Parkway,Suite 500,Las Vegas,Nevada,United States
Zip Code:
89169
Fax:
917 595 2851
Introduction:
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Directors

Name
Position
Joshua N. Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Jonathan L. Schechter
Director
Michael M. Abecassis
Director
Robert Weinstein
Director
Wayne R. Walker
Director

Shareholders

Name
Position
Joshua N. Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Carlos A. Trujillo
Chief Financial Officer